Enriched NK Cell Subsets Enhance Antibody-Directed Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-based therapies for cancer and other diseases have limited effectiveness due to insufficient activation of the host immune system, particularly in mediating antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells.
Innovation Solution
Development of specialized subsets of NK cells with enhanced antibody-directed immune responses, specifically CD16 158V+ and FcRy-deficient NK cells, which exhibit increased affinity for IgG antibodies and enhanced ADCC capabilities, are enriched and administered in combination with antibodies to target tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NK cells are administered with antibody therapy, then the treatment can be provided, but the antibody-directed immune response is insufficient and ADCC activity is limited
Solution Approach 1:
The patent applies parameter changes by selecting and enriching NK cells with specific genetic polymorphisms (CD16 158V allele and FcRγ chain deficiency) that inherently possess enhanced ADCC activity. This genetic parameter selection transforms conventional NK cells into specialized subsets with improved antibody-directed immune responses and cytotoxic effectiveness.
Solution Approach 2:
The patent employs local quality by creating heterogeneous NK cell populations with distinct functional characteristics. Specifically, it enriches for NK cells expressing either the CD16 158V allele or deficient in FcRγ chain, each subset providing localized functional advantages in mediating ADCC and cytokine production against targeted cells.
2Reliability
If NK cells with enhanced ADCC capabilities are enriched and administered, then therapeutic outcomes are improved, but the complexity of cell selection and preparation increases
Solution Approach 1:
The patent applies preliminary action by pre-enriching NK cells with desired genetic characteristics (CD16 158V+ or FcRγ chain-deficient) before administration. This advance selection and expansion of specialized NK cell subsets ensures that the therapeutic product contains the required functional properties for enhanced ADCC activity, eliminating the need for complex post-administration selection processes.
Data Source
Figure 1
AI summary
Provided herein are compositions containing specialized subsets of natural killer (NK) cells with enhanced antibody-directed immune responses. The compositions are useful for treating diseases and conditions such as cancer, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.